Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Alabama Dept. of Public Health Proposes Civil Penalty Against Company For Failing To Properly Maintain Security, Accountability Of Radioactive s
The Alabama Department of Public Health has proposed a $650 civil penalty against

Trubion Announces Positive Data From A Phase 1 / 2 Study Of TRU-016 For The Treatment Of Chronic Lymphocytic Leukemia (CLL)
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced the presentation of encouraging Phase 1 safety and efficacy results following administration of low doses of TRU-016 in heavily pre-treated patients with high-risk genomic factors and relapsed or refractory chronic lymphocytic leukemia (CLL). TRU-016 is the Company"s proprietary anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate.
News of the day
NOW Election Highlights Debate Over Strategy For Future Of Feminist Movement
The AP/Kansas City Star on Sunday examined how the upcoming election for the next president of the National Organization for Women has brought to the forefront a debate over how the feminist movement should define itself moving forward. NOW President Kim Gandy is stepping down after eight years in which she led the group in opposition to many of former President George W. Bush"s policies. Running to replace her are Latifa Lyles, a 33-year-old who serves as a vice president to Gandy, and Terry O"Neill, a 56-year-old who served as NOW"s vice president for membership from 2001 to 2005. Lyles, who is black, would be NOW"s youngest president while O"Neill, who is white, would be its oldest to start a term. According to the AP/Star, the election represents "both an unusual clash of generations and an opportunity for activists to confront some of the challenges facing the feminist movement." The election will be held at NOW"s conference in Indianapolis this weekend.The candidates share the goals of ensuring that women"s needs are represented in health care reform and economic recovery efforts, and they both support working to make abortion and birth control more accessible. Lyles said she contrasts with NOW"s current membership, which is mostly white and older than age 40. Lyles believes she could help give the organization a more diverse, younger image and help encourage participation from a broader range of women. "The profile of NOW is just as important as the work we do," she said, adding, "There are a lot of antiquated notions about what feminism is." Gandy, who has endorsed Lyles, said, "It"s hard to ignore the fact there"s been a generational shift in the country, and an organization that doesn"t recognize that is living in the past." She added that Lyles" "youth is not a detriment, but an advantage. ... She"ll take NOW to a different level." Jessica Valenti, a prominent younger feminist and founder of the blog Feministing, said, "This could be the moment where NOW becomes super-relevant to the feminist movement again."O"Neill said she would focus on grassroots organizing and membership recruitment. She said that "even with a friend in the White House and a lot of friends in the Congress, it"s going to take well-organized, grassroots movement to advance our agenda." O"Neill added, "I keep hearing "Terry, I want to see more activism in my community,"" adding, "The press releases, the media exposure, invitations to the White House -- these are excellent things, but they"re not enough. The grass roots are not personally engaged." Former NOW President Patricia Ireland, who supports O"Neill, said, "There is a role that requires us to take unpopular stands and push on our friends. That"s what I think [O"Neill] really gets. She"s the one I believe will be very willing to use a wide array of tactics -- not just traditional letters and e-mails, but also engage in civil disobedience, organize fasts, be at some congressman"s district office" (Crary, AP/Kansas City Star, 6/14).
Medical Devices

Whole Genome Sequencing Of Multiple Myeloma Samples To Be Performed By MMRF And The Broad Institute

The Multiple Myeloma Research Foundation (MMRF) has announced a collaboration with the Broad Institute of MIT and Harvard to systematically uncover the molecular changes underlying multiple myeloma by whole genome sequencing of individual patient tumors. The MMRF will provide both patient samples for analysis as well as funding for the project. All data from this collaboration will be put in the public domain. "We are delighted to work with the MMRF, which has been a visionary organization in accelerating cancer research for the sake of patients and their families," said Eric S. Lander, PhD, Director of the Broad Institute. "Through our work together on this critical pilot project in whole cancer genome sequencing, we hope not only to advance clinical progress for multiple myeloma, but to build knowledge and technical capabilities that can be applied to many other human cancers." "Three years ago, the MMRF launched a partnership with the Broad Institute and the Translational Genomics Research Institute - the Multiple Myeloma Genomics Initiative - a comprehensive genome mapping program to identity new targets and eventually new therapies for this incurable disease," said Kathy Giusti, Founder and CEO of the MMRF, and a multiple myeloma patient. "As part of that larger effort, we are confident that this groundbreaking research will accelerate the development of next-generation treatments to extend the lives of multiple myeloma patients. Additionally, we believe that this work will not only ultimately pave the way to a cure for patients with multiple myeloma, but will benefit patients with other types of cancer." The creation of comprehensive catalogs of all commonly occurring cancer mutations is a current approach of several national and international consortia, including The Cancer Genome Atlas (TCGA) led by the US National Institutes of Health and the International Cancer Genome Consortium (ICGC), to understand major tumor types such as leukemia, lung cancer, glioblastoma and others. To date, only a handful of whole cancer genomes have been sequenced and only one has been published. "The few cancer genomes sequenced to date have been informative, but we need many more to transform cancer research and ultimately cancer therapy," said Stacey Gabriel, PhD, Co-Director of the Broad Institute"s Genome Sequencing and Analysis Program. "This exciting collaboration with the MMRF will advance these goals by contributing public domain data." Nicole Davis Broad Institute of MIT and Harvard


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009